Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A DeCrescenzo

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 10, 2010
MMP-13 selective isonipecotamide alpha-sulfone hydroxamatesStephen A Kolodziej, Susan L Hockerman, Gary A DeCrescenzo, et al.
Bioorganic & Medicinal Chemistry Letters|June 10, 2010
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamatesStephen A Kolodziej, Susan L Hockerman, Terri L Boehm, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Physiochemical drug properties associated with in vivo toxicological outcomesJason D Hughes, Julian Blagg, David A Price, et al.
Journal of Medicinal Chemistry|October 14, 2005
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacyDaniel P Becker, Clara I Villamil, Thomas E Barta, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal of Medicinal Chemistry|August 24, 2010
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular diseaseDaniel P Becker, Thomas E Barta, Louis J Bedell, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|June 10, 2010
MMP-13 selective isonipecotamide alpha-sulfone hydroxamatesStephen A Kolodziej, Susan L Hockerman, Gary A DeCrescenzo, et al.
Bioorganic & Medicinal Chemistry Letters|June 10, 2010
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamatesStephen A Kolodziej, Susan L Hockerman, Terri L Boehm, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Physiochemical drug properties associated with in vivo toxicological outcomesJason D Hughes, Julian Blagg, David A Price, et al.
Journal of Medicinal Chemistry|October 14, 2005
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacyDaniel P Becker, Clara I Villamil, Thomas E Barta, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal of Medicinal Chemistry|August 24, 2010
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular diseaseDaniel P Becker, Thomas E Barta, Louis J Bedell, et al.
Pageof 1